diff --git a/DESCRIPTION b/DESCRIPTION
index d10b7d0e6754f979cbb76ef90a5f770d740819d7..71c1aed47bcddad68d711958c1b25cc3d3d346a9 100644
--- a/DESCRIPTION
+++ b/DESCRIPTION
@@ -2,7 +2,7 @@ Package: bayesmeta
Type: Package
Title: Bayesian Random-Effects Meta-Analysis and Meta-Regression
Version: 3.3
-Date: 2023-01-12
+Date: 2023-03-16
Authors@R: c(person(given="Christian", family="Roever", role=c("aut","cre"),
email="christian.roever@med.uni-goettingen.de",
comment=c(ORCID="0000-0002-6911-698X")),
diff --git a/data/Peto1980.R b/data/Peto1980.R
index 74eb07cb5c61e8709e1f27293f39b93f5e19e626..ca6e57c137befd40fff1aa1e670c0e08f395646c 100644
--- a/data/Peto1980.R
+++ b/data/Peto1980.R
@@ -1,15 +1,23 @@
#
-# S.E. Brockwell, I.R. Gordon. A comparison of statistical methods for meta-analysis.
-# Statistics in Medicine, 20(6):825-840, 2001.
-#
# R. Peto. Aspirin after myocardial infarction.
# The Lancet 315(8179):1172-1173, 1980.
+# https://doi.org/10.1016/S0140-6736(80)91626-8
+#
+# P.L. Canner. An overview of six clinical trials of aspirin in coronary heart disease.
+# Statistics in Medicine, 6(3):255-263, 1987.
+# https://doi.org/10.1002/sim.4780060310
#
Peto1980 <- cbind.data.frame("publication" =c("BrMedJ1974","JChronDis1976","Haemostasis1980",
"Lancet1979","JAMA1980","Circulation1980"),
- "treat.cases" =c(615, 758, 317, 832, 810, 2267),
- "treat.events" =c(49, 44, 27, 102, 85, 246),
- "control.cases" =c(624, 771, 309, 850, 406, 2257),
- "control.events"=c(67, 64, 32, 126, 52, 219),
+ "study" =c("UK-1","CDPA","GAMS","UK-2","PARIS","AMIS"),
+ "start" =as.integer(c(1971, 1972, 1970, 1975, 1975, 1975)),
+ "end" =as.integer(c(1973, 1975, 1977, 1979, 1979, 1979)),
+ "age" =c(55.0, 56.5, 58.9, 56.2, 56.3, 54.8),
+ "dose" =c(300, 972, 1500, 900, 972, 1000),
+ "followup" =c(11.9, 22.0, 24.0, 12.0, 41.0, 39.6),
+ "treat.cases" =as.integer(c(615, 758, 317, 832, 810, 2267)),
+ "treat.events" =as.integer(c(49, 44, 27, 102, 85, 246)),
+ "control.cases" =as.integer(c(624, 771, 309, 850, 406, 2257)),
+ "control.events"=as.integer(c(67, 64, 32, 126, 52, 219)),
stringsAsFactors=FALSE)
diff --git a/man/KarnerEtAl2014.Rd b/man/KarnerEtAl2014.Rd
index 303008890a0e3e3951bc093359876b628b5b53c0..3ab57cd39046d0fd1eb457071cc4cff37d3e09a3 100644
--- a/man/KarnerEtAl2014.Rd
+++ b/man/KarnerEtAl2014.Rd
@@ -12,7 +12,7 @@
\bold{inhaler} \tab \code{factor} \tab type of inhaler investigated (\dQuote{dry powder} or \dQuote{soft mist}) \cr
\bold{baseline.age} \tab \code{numeric} \tab mean age at baseline \cr
\bold{baseline.males} \tab \code{numeric} \tab proportion of males among study participants \cr
- \bold{baseline.fev1} \tab \code{numeric} \tab mean FEV1 at baseline \cr
+ \bold{baseline.fev1} \tab \code{numeric} \tab mean FEV1 at baseline (L) \cr
\bold{baseline.fev1pp} \tab \code{numeric} \tab mean FEV1 (percent of predicted) at baseline \cr
\bold{baseline.pyr} \tab \code{numeric} \tab mean number of pack-years (smoking history) \cr
\bold{tiotropium.total} \tab \code{numeric} \tab total number of patients in the treatment group \cr
@@ -30,7 +30,7 @@
\bold{placebo.sae} \tab \code{numeric} \tab number of patients with \eqn{\geq 1}{>=1} serious adverse event (non-fatal) in the control group \cr
\bold{placebo.dropout} \tab \code{numeric} \tab number of withdrawals in the control group \cr
\bold{sgrq.md}, \bold{sgrq.se} \tab \code{numeric} \tab mean difference and associated standard error for \emph{St. George's respiratory questionnaire (SGRQ)} total score \cr
- \bold{fev1.md}, \bold{fev1.se} \tab \code{numeric} \tab mean difference and associated standard error for \emph{forced expiratory volume in 1 second (FEV1)} \cr
+ \bold{fev1.md}, \bold{fev1.se} \tab \code{numeric} \tab mean difference and associated standard error for \emph{forced expiratory volume in 1 second (FEV1, mL)} \cr
}
}
\details{Chronic obstructive pulmonary disease (COPD) is a chronic and
@@ -38,7 +38,8 @@
phases. Various treatment options are available, aimed at both
providing relief during an acute exacerbation, and at delaying overall
disease progression. A common drug used in the management of COPD is
- \emph{tiotropium}, which is administered via an inhaler device.
+ \emph{tiotropium}, a long-acting muscarinic antagonist (LAMA), which
+ is administered via an inhaler device.
Karner \emph{et al.} (2014) conducted a systematic review in order to
evaluate the evidence on the effects of tiotropium in comparison to
diff --git a/man/Peto1980.Rd b/man/Peto1980.Rd
index 896eb079733df4b825808e82aacdf129292f33ec..4144d12710b00cb0b51e39b3aa8a0ba5fa7e0f82 100644
--- a/man/Peto1980.Rd
+++ b/man/Peto1980.Rd
@@ -7,24 +7,37 @@
\usage{data("Peto1980")}
\format{The data frame contains the following columns:
\tabular{lll}{
- \bold{publication} \tab \code{character} \tab publication identifier \cr
- \bold{treat.cases} \tab \code{numeric} \tab number of cases in treatment group \cr
- \bold{treat.events} \tab \code{numeric} \tab number of events in treatment group \cr
- \bold{control.cases} \tab \code{numeric} \tab number of cases in control group \cr
- \bold{control.events} \tab \code{numeric} \tab number of events in control group \cr
+ \bold{publication} \tab \code{character} \tab publication reference \cr
+ \bold{study} \tab \code{character} \tab study acronym or abbreviation \cr
+ \bold{start}, \bold{end} \tab \code{integer} \tab duration of study (calendar years) \cr
+ \bold{age} \tab \code{numeric} \tab mean patient age (years) \cr
+ \bold{dose} \tab \code{numeric} \tab total daily dose (mg) \cr
+ \bold{followup} \tab \code{numeric} \tab follow-up duration (months) \cr
+ \bold{treat.cases} \tab \code{integer} \tab number of cases in treatment group \cr
+ \bold{treat.events} \tab \code{integer} \tab number of events in treatment group \cr
+ \bold{control.cases} \tab \code{integer} \tab number of cases in control group \cr
+ \bold{control.events} \tab \code{integer} \tab number of events in control group \cr
}
}
\details{
- Quoting from Brockwell and Gordon (2001):
- \dQuote{The collection consists of six studies, each examining the
- effect of aspirin after myocardial infarction. In each study the
- number of patients who died after having been given either aspirin
- or a control drug is recorded.}
+ Peto (1980) investigated mortality data from six randomized,
+ placebo-controlled clinical trials of aspirin, involving a total of
+ 10,703 post-myocardial infarction patients. Canner (1987) later investigated
+ potential heterogeneity between study characteristics as well as their
+ reported estimates. The included studies' abbreviations are:
+ \tabular{ll}{
+ UK-1 \tab first United Kingdom trial \cr
+ CDPA \tab Coronary Drug Project Aspirin trial \cr
+ GAMS \tab German-Austrian Multicentre Study\cr
+ UK-2 \tab second United Kingdom trial \cr
+ PARIS \tab Persantine-Aspirin Reinfarction Study \cr
+ AMIS \tab Aspirin Myocardial Infarction Study
+ }
}
-\source{S.E. Brockwell, I.R. Gordon.
- A comparison of statistical methods for meta-analysis.
- \emph{Statistics in Medicine}, \bold{20}(6):825-840, 2001.
- \doi{10.1002/sim.650}.
+\source{P.L. Canner. An overview of six clinical trials of aspirin
+ in coronary heart disease.
+ \emph{Statistics in Medicine}, \bold{6}(3):255-263, 1987.
+ \doi{10.1002/sim.4780060310}
}
\references{R. Peto.
Aspirin after myocardial infarction.
diff --git a/man/bayesmeta-package.Rd b/man/bayesmeta-package.Rd
index 5fe43fd0cc560fb94c99753952bc19d8049b376d..975dd7080fb2ab86287788941c6c4cf1d490c537 100644
--- a/man/bayesmeta-package.Rd
+++ b/man/bayesmeta-package.Rd
@@ -16,7 +16,7 @@
Package: \tab bayesmeta\cr
Type: \tab Package\cr
Version: \tab 3.3\cr
- Date: \tab 2022-01-12\cr
+ Date: \tab 2023-03-16\cr
License: \tab GPL (>=2)
}
The main functionality is provided by the \code{\link{bayesmeta}()}